Beike Biotechnology

What Beike Biotechnology does

Beike Biotechnology (Shenzhen Beike Biotechnology Co., Ltd.), founded in July 2005 and headquartered in Shenzhen, China, is a privately held biotechnology company that describes itself as the world's largest adult stem cell provider, focused on the research, development, and clinical translation of adult stem cell therapies and immunotherapies. Its core platform produces umbilical cord blood-derived stem cells (UCBSC) and umbilical cord-derived mesenchymal stem cells (UCMSC), administered at 30+ partner hospitals across China and through international medical tourism channels (notably Better Being Hospital in Bangkok) to treat neurological conditions, spinal cord injuries, cerebral palsy, ALS, multiple sclerosis, vascular diseases, and other chronic or currently incurable illnesses. The proprietary MAR (Major Histocompatibility Antigen Receptor) and TriTE (Tri-functional T cell Engager) platforms underpin a second franchise in cancer immunotherapy, including MAR-T cell therapies, MCAR-T and MCAR-NK product lines, BiAT bi-specific antibodies, and the China-licensed ALT-803 IL-15 superagonist from Altor Bioscience. Affiliated subsidiaries Timmune and Transimmune Biotech (formed through the 2015 acquisition of Nanjing Abingen Biotech) carry the immunotherapy pipeline.

Revenue mechanics are diversified across four streams: per-procedure stem cell supply to domestic partner hospitals, international medical tourism treatments (one reported $50,000 procedure in Thailand), cell banking subscriptions through the Shenzhen Integrated Cell Bank and Jiangsu Stem Cell Bank, and licensing/royalty economics from the immunotherapy portfolio. The company supports operations with 25 GMP-standard laboratories, a 20,000 sqm Taizhou facility storing up to 1 million samples, AABB/ISO/CNAS certifications, ~50 peer-reviewed publications including in Nature, and 700+ employees of whom 60+ hold PhDs from top Chinese universities with prior tenure at Stanford, University of Minnesota, and UCLA. The company has cumulatively treated over 20,500 patients and received over US$6 million in government grants, but does not publicly disclose revenue.

Name

Beike Biotechnology

Legal name

Beike Biotechnology Co., Ltd.

Website

https://beikebiotech.com

Company type

Private

Founded year

2005

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Beike Biotechnology is a Shenzhen-based biotech company and self-described world's largest adult stem cell provider, treating neurological, vascular, and oncological conditions through 30+ Chinese partner hospitals and international medical tourism, with proprietary MAR/TriTE cancer immunotherapy platforms.

Ownership category

akta.pro rank

Product category

Regenerative Medicine - Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), NK Cell Therapies (HLAAABAD), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Stem cell therapy
• Regenerative medicine
• Cell banking services
• Cancer immunotherapy
• Biopharmaceutical research

Headquarters

HQ city

Shenzhen

HQ country

China

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Stem Cell Therapy Products: Beike provides stem cells to partner hospitals for clinical treatment of patients. The company maintains full oversight over cell manufacturing, from testing of blood products, to cell processing at their laboratories, to delivery of cells for clinical use.
2. Cell Banking Services: Stem cell collection, storage and banking services through Shenzhen Integrated Cell Bank and regional cell preparation centers.
3. Cell Processing Laboratory Services: Provides cell processing laboratory services to partner hospitals and medical institutions.
4. Immunotherapy Products: Development and commercialization of immunotherapy products including ALT-803, CAR-T products, and MAR-based antibody therapies.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels6 records

Core offering

Beike Biotechnology is the world's largest stem cell provider focusing on the research, development, and clinical translation of adult stem cells. The company produces umbilical cord blood-derived and umbilical cord-derived mesenchymal stem cells, providing them to 30+ partner hospitals in China for treatment of neurological, vascular, and degenerative conditions. In addition, Beike develops proprietary immunotherapy products including CAR-T variants (MAR-T), bi-specific antibodies (BiAT), and NK cell therapies (MCAR-NK) using its MAR and TriTE technology platforms, with the licensed ALT-803 IL-15 superagonist for cancer treatment.

Product overview

Beike Biotechnology operates as a biotechnology company offering stem cell therapies and immunotherapies through multiple integrated platforms and services. The core product portfolio includes adult stem cell therapies (umbilical cord blood-derived and umbilical cord-derived mesenchymal stem cells) for treatment of neurological, vascular, and optic conditions. The immunotherapy portfolio includes proprietary MAR and TriTE technology platforms powering CAR-T variants (MAR-T), bi-specific antibodies (BiAT), and NK cell therapies (MCAR-NK). Key products include ALT-803 (IL-15 superagonist licensed from Altor Bioscience), with subsidiaries Timmune and Transimmune developing cell therapies and fusion protein drugs. Supporting infrastructure includes the Shenzhen Integrated Cell Bank for stem cell storage and the Shenzhen Regional Cell Preparation Center for GMP-compliant cell manufacturing. The company has treated over 20,500 patients and provides services to more than 30 partner hospitals in China.

Differentiator

Problem solved

Functional benefit

Products and services

• Umbilical Cord Blood-Derived Stem Cells (UCBSC) Stem cell injections derived from umbilical cord blood containing three subsets of stem cells: hematopoietic stem cells, endothelial progenitor cells, and mesenchymal stem cells. Used for treatment of conditions including spinal muscular atrophy, ataxia, and optic nerve conditions.
• Umbilical Cord-Derived Mesenchymal Stem Cells (UCMSC) Stem cell injections containing a higher percentage of mesenchymal stem cells than UCB stem cell injections. Recommended for multiple sclerosis (MS) and spinal cord injury (SCI) patients. Produces growth factors, differentiates into desired cell types, and modulates the immune system.
• ALT-803 (IL-15 Superagonist) Potent immunotherapeutic agent capable of activating immune cell responses against hematologic and solid tumors and virally infected cells. Licensed from Altor Bioscience for China development and commercialization.
• MAR-T Cell Therapy Variant of CAR-T for adoptive T cell cancer therapy utilizing proprietary TriTE platform and MAR. Results in T cells with improved micro-environment functions, higher number of binding targets with better binding specificity and affinity.
• MCAR-T Series (MAR-based CAR-T) MAR-based CAR-T cell therapy product line with distinct advantage over regular CAR-T in wider spectrum of target binding. Includes MCAR-T/GP100 for solid tumor treatment.
• MCAR-NK Series (MAR-based CAR-NK) MAR-based NK cell therapy product line including MCAR-NK/GP100 for solid tumor treatment with wider spectrum of target binding compared to regular NK cell therapies.
• BiAT Bi-specific Antibody Bi-specific antibody fusion protein drug candidates using MAR as target binding end combined with T cell engagers. Includes BiAT HER2/CD3, CD20/CD3, and EGFR/CD3 for various cancer applications.
• CSF Safe-A Cell Freeze Solution Specially developed for immune cell freezing and storage. Part of laboratory products serving cell therapy and cell banking industry.
• Shenzhen Integrated Cell Bank Stem cell collection, storage and banking services. Collects and stores stem cells from umbilical cord, placenta, fat, deciduous teeth, and adult peripheral blood sources. AABB accredited for cord blood processing, storage, distribution, cell therapy activity, somatic cell processing, storage, and distribution.
• Shenzhen Regional Cell Preparation Center Regional cell preparation center for south China region, located at Beike Biotechnology headquarters. Provides GMP-compliant cell manufacturing services for clinical translation of cell therapy.
• Stem Cell Treatment Services Clinical cell therapy services treating over 20,500 patients since 2005. Provides treatments for neurological conditions (cerebral palsy, spinal cord injury, ALS, multiple sclerosis, ataxia), vascular conditions, optic nerve conditions, and various other conditions. Administered through 30+ partner hospitals in China and through international medical tourism channels including Better Being Hospital in Thailand.

Quantifiable outcome

• Over 20,500 patients treated since 2005
• +6 more outcomes

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

18 partnerships are on record, tiered strategic, core and minor.

• Karolinska Institute (Sweden)strategicStrategic or Co-development Partner · 18 October 2016Delegation from Sweden's Karolinska Institute visited Beike headquarters to explore medical research cooperation. Focus areas include regenerative medicine, cancer research, and clinical application of cell therapy technology. Both parties seek to strengthen exchanges in basic stem cell research.
• 11 Shenzhen HospitalscoreImplementation/ SI/ Consulting Partner · 19 November 2015Strategic partnership through Shenzhen Clinical Translation Platform for Personalized Cell Therapy. Includes Luohu Group Hospital, Shenzhen Second People's Hospital, Shenzhen Maternity & Child Healthcare Hospital, and others.
• Nanjing Abingen Biotech Co. Ltd. (Transimmune Biotech Inc.)strategicStrategic or Co-development Partner · 1 January 2015Acquired innovative immunotherapy developer with proprietary technologies and products. Led to formation of Transimmune Biotech Inc. as Beike's affiliated company for innovative immunotherapeutic programs including BiAT antibodies and CAR-T products.
• Altor Bioscience CorporationcoreStrategic or Co-development Partner · 9 September 2014License agreement to develop and commercialize ALT-803, Altor's proprietary IL-15 superagonist, in China. Beike participates in Phase 3 clinical trials and manages approval and commercial activities in China. ALT-803 is considered one of the most promising therapeutic agents by National Cancer Institute.
• Tsinghua University (Shenzhen Graduate School)coreStrategic or Co-development Partner · 7 November 2007Established world-class joint laboratory for cell reprogramming and gene engineering research. USD $4 million grant from Shenzhen Municipal Government for equipment. Lab focuses on stem cells, nuclear transfer, reprogramming, and monoclonal antibodies. Staffed by 50+ researchers including 20 renowned Chinese PhDs.
• Biomaster Inc. (Japan)strategicStrategic or Co-development Partner · 4 November 2007Investment partnership with Yokohama-based regenerative medicine company specializing in adipose-based stem cell therapies. Beike took significant share and board seat. Biomaster is the only company in Japan authorized to offer stem-cell based therapies publicly.
• Better Being Hospital (Thailand)coreImplementation/ SI/ Consulting PartnerInternational treatment partnership for administering stem cell therapies to international patients. Dr. Torsak leads the collaboration, representing commitment to highest quality clinicians and clinics worldwide.
• Huazhong University of Science and TechnologycoreStrategic or Co-development PartnerResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
• Sun Yat-Sen UniversitycoreStrategic or Co-development PartnerResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
• Chinese University of Hong KongcoreStrategic or Co-development PartnerResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
• Zhengzhou UniversitycoreStrategic or Co-development PartnerResearch partnership in biotechnology research alliance. One of multiple prestigious universities in Beike's research network.
• Blood Transfusion Institute of Military Medical Science Academy of the PLAcoreStrategic or Co-development PartnerResearch partnership in biotechnology research alliance. One of multiple prestigious institutions in Beike's research network.
• PLA Navy General HospitalcoreStrategic or Co-development PartnerResearch partnership in biotechnology research alliance. One of multiple prestigious institutions in Beike's research network.
• Xijing Hospital of the Fourth Military Medical UniversitycoreStrategic or Co-development PartnerResearch partnership in biotechnology research alliance. One of multiple prestigious institutions in Beike's research network.
• National Innovation Strategic Alliance of Stem Cell and Regenerative Medicine IndustrystrategicStrategic or Co-development PartnerBeike is a member of this national alliance. Dr. Xiang (Sean) Hu serves as vice chairman. Jiangsu Beike is the organizer of Jiangsu Provincial Innovation Strategic Alliance of Stem Cell Industry.
• Cerebral Palsy SupportminorGTM or Marketing PartnerPartnership with Cerebral Palsy Support website providing information for parents of children diagnosed with cerebral palsy.
• ECM MedicalminorGTM or Marketing PartnerMarketing partnership with ECM Medical.
• LingolanderminorGTM or Marketing PartnerMarketing partnership with Lingolander.

Scale indicators11 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Athersys: Clinical-stage cell therapy company developing MultiStem (multipotent adult progenitor cell) for stroke, ARDS, and trauma; comparable as a peer using off-the-shelf adult stem cells in regenerative medicine indications.
• Pharmicell: Korean stem cell company with an approved autologous bone marrow MSC therapy (Cartistem) and a bank/clinical-translation model; closely comparable to Beike's cord blood and bone-marrow derived MSC business.
• CARsgen Therapeutics: China-based CAR-T developer with both hematologic and solid-tumor programs; directly comparable to Beike's MCAR-T/GP100 solid-tumor strategy and Chinese regulatory pathway.
• JW Therapeutics: China-based CAR-T developer with an approved CD19 CAR-T product (Carteyva); closely comparable to Beike's MAR-T, MCAR-T, and CAR-T pipeline on geography, modality, and target antigens.
• Medipost: Korean biotech with an approved allogeneic umbilical cord blood MSC product (Cartistem/Cupistem) and a cell banking business; directly comparable to Beike's UCMSC therapy and cord blood banking operations.
• Cellular Biomedicine Group: China-based cell therapy company developing immune-cell and stem cell therapies for cancer and degenerative diseases; directly comparable as a Chinese peer operating in the same regulatory and clinical environment as Beike.
• Mesoblast: Commercial-stage developer of mesenchymal stem cell (MSC) therapies for inflammatory and immune-mediated diseases; directly comparable to Beike's UCMSC franchise on cell type, indications, and scale-up model.

Broad incumbents

• Bristol Myers Squibb: Major oncology company with approved CAR-T products (Breyanzi, Abecma) and active cell therapy development; sets the standard Beike's MAR-T/MCAR-T programs would need to differentiate against in oncology.
• Novartis: Global pharma with the first approved CAR-T (Kymriah) and active cell therapy investment; broad incumbent whose pricing, distribution, and clinical evidence define the bar for new entrants like Beike.
• Bluebird Bio: Established gene and cell therapy company with multiple approved and clinical-stage autologous therapies; relevant as a broad incumbent in cell-based medicine that competes for the same clinical and capital mindshare as Beike.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/beikebiotech
• YouTubeyoutube.com/user/Beikebiotechnology
• Facebookfacebook.com/beikebiotech
• LinkedInlinkedin.com/company/beike-biotechnology

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Beike Biotechnology